Enjoy complimentary customisation on priority with our Enterprise License!
The breast cancer monoclonal antibodies market size is estimated to grow by USD 19.2 billion at a CAGR of 13.97% between 2023 and 2028. The incidence of breast cancer continues to rise, making it a significant global health concern. According to the World Health Organization, breast cancer is the most common cancer among women worldwide. In response to this growing issue, there has been an increasing number of patient support initiatives aimed at raising awareness and advocating for early detection and treatment. Furthermore, the demand for minimally invasive therapies for breast cancer treatment is on the rise. These innovative treatments offer several advantages, including reduced recovery time, fewer side effects, and improved patient outcomes. Minimally invasive procedures, such as stereotactic biopsy and radiofrequency ablation, are becoming increasingly popular alternatives to traditional surgical methods. These advancements in breast cancer care are crucial in improving patient outcomes and quality of life.
The increased number of patient support initiatives for breast cancer awareness is to address the economic and emotional burden associated with breast cancer. Pharmaceutical manufacturers, governments, non-profits, and healthcare providers are striving to improve patient access to resources and close significant healthcare gaps. The Novartis Solutions (STEP) Program for Empowering Patients supports non-profit organizations that provide innovative solutions to the metastatic breast cancer community. Moreover, government organizations such as the Centers for Disease Control and Prevention (CDC) in the US are increasingly offering support to people with breast cancer. Susan G. Komen is a US non-profit organization that partnered with CancerCare to create the Komen Treatment Assistance Program to help cancer patients to overcome financial hardships. Hence, the increasing number of patient support and education programs for breast cancer is expected to drive the growth of the market during the forecast period.
To learn more about this report, Request Free Sample
The market share growth by the hospital segment will be significant during the forecast period. Hospitals play an important role in the diagnosis, treatment, and management of breast cancer. Monoclonal antibodies have become an essential part of breast cancer treatment in hospitals owing to their highly targeted mechanism of action and efficacy in combating cancer cells. Hospitals often serve as primary centers for breast cancer diagnosis. Hospitals are offering monoclonal antibody drug therapy directly to patients as part of breast cancer treatment plans.
Get a glance at the market contribution of various segments View a PDF Sample
The hospital segment was valued at USD 6.30 billion in 2018. The increasing number of cancer hospitals across the globe is also supporting the growth of this segment. In this segment, breast cancer is one of the major diagnosed cancer in women across the globe. Although early diagnosis is used as a preventive approach, the risk of breast cancer remains unchanged. Furthermore, the hospital conducts clinical trials and research activities related to breast cancer monoclonal antibodies. They work with pharmaceutical companies and research organizations to discover new monoclonal antibody therapies, contribute to clinical trials, and advance the development of personalized therapeutic approaches for breast cancer patients. Hence, the rising incidence of breast cancer and growing awareness about the early detection of and personalized treatments for the disease will drive the growth of the segment during the forecast period.
The human segment refers to monoclonal antibodies that are derived from humans or that have been engineered to closely resemble human antibodies. These antibodies are made to have a lower risk of immune reaction and improved efficacy compared to non-human and chimeric antibodies. Prominent vendors in the market offering human-type monoclonal antibodies for breast cancer treatment include Roche, Pfizer, and Novartis. These companies continue to invest in research and development to further improve the efficacy and safety of human monoclonal antibodies for breast cancer patients. Besides, advancements in antibody engineering techniques have enabled the development of more potent and targeted human-type monoclonal antibodies for the treatment of breast cancer, which is expected to fuel the growth of the human segment of the market during the forecast period.
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Technological advances and the increasing prevalence of breast cancer have raised the demand for monoclonal antibodies in the region. The growing adoption of personalized medicine, the need for early detection of breast cancer, and the development of targeted therapies are the key factors driving the growth of the market in this region. North America boasts a strong healthcare infrastructure, expertise in genomics research, and widespread access to monoclonal antibodies.
Moreover, North America has many established medical facilities with state-of-the-art infrastructure and advanced treatment solutions. Medical facilities in the region focus on targeted therapies to treat various types of cancer, including breast cancer. This has led to the demand for personalized medicine and the development of associated monoclonal antibodies. Hence, these factors combined with the growing incidence of breast cancer, will contribute to the growth of the North American market during the forecast period.
Buy Now Full Report and Discover More
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Amgen Inc.: The company offers breast cancer monoclonal antibodies such as KANJINTI.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market is advancing with therapeutic drugs like immune system inhibitors targeting HER2 and triple negative breast cancers, emphasizing antigen specificity. Innovations in bispecific and trispecific mAbs are enhancing treatment efficacy, alleviating symptoms such as fever, trembling, itching, weakness, and chills associated with estrogen receptor and progesterone receptor positive cancers. These systemic therapies, including monoclonal antibody drugs developed through hybridoma technology, are crucial for patients with BRCA gene mutations. Both conjugated antibodies and naked monoclonal antibodies play vital roles in managing inflammation and improving outcomes, despite potential side effects like low blood pressure and low blood cell counts. The market's growth is driven by continuous research into novel therapies and personalized medicine approaches for breast cancer treatment. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
Increasing demand for minimally invasive therapies for breast cancer treatment is the key factor driving the growth of the market. Minimally invasive therapies, such as targeted monoclonal antibody therapy, are gaining importance owing to their potential to provide effective treatments that are less invasive and have fewer side effects. Unlike traditional chemotherapy or surgery, minimally invasive therapies, including monoclonal antibody therapy, target specific cancer cells or molecules and cause minimal damage to healthy tissue. This targeted approach not only improves patient outcomes but also the quality of life for breast cancer patients by reducing associated complications and recovery times.
Moreover, Shorter hospital stays, reduced pain and discomfort, and faster recovery are the key factors driving the growth of minimally invasive therapies. Breast cancer patients are mainly seeking these alternatives to traditional treatments that often involve more invasive procedures, longer hospital stays, and extended recovery periods. Hence, this demand is expected to boost the growth of the market during the forecast period.
The growing number of strategic collaborations is the trend in the market. To develop the best therapies to treat breast cancer, major manufacturers are acquiring therapies from other manufacturers through multi-billion dollar collaborations. For example, in August 2021, Gilead Sciences and Merck (MSD) entered into a clinical trial partnership and supply agreement to evaluate the efficacy of former Trodelby with Keytruda in the treatment of triple-negative breast cancer (TNBC). This combination therapy is being analyzed as first-line therapy for patients with locally advanced or metastatic TNBC.
Moreover, Eisai Co., Ltd. and Bristol-Myers Squibb also announced in June 2021 that they entered into an exclusive global strategic collaboration agreement to co-develop and co-commercialize MORAb-202, an antibody-drug conjugate (ADC). MORAb-202 is Eisai's first ADC, combining Eisai's proprietary anti-folate receptor alpha (FR) antibody and anti-cancer drug eribulin with an enzymatically cleavable linker. Hence, such collaborations are expected to boost the growth of the market during the forecast period.
Side effects and safety concerns associated with breast cancer monoclonal antibody treatment are the challenges that affect the growth of the market. Monoclonal antibody therapy has proven effective in treating breast cancer, but emerging side effects and long-term safety concerns may hamper patient acceptance and market growth. Patients may be reluctant to undergo monoclonal antibody treatment or discontinue treatment because of the burden of these side effects. This may lead to lower patient adherence and consequently limit the market growth potential of breast cancer monoclonal antibodies.
Furthermore, safety concerns about the long-term use of monoclonal antibodies may also discourage patients and healthcare professionals from using these treatments. These concerns may influence patient decision-making and provider prescribing behavior. Thus, this factor will impede the growth of the market during the forecast period.
Buy Now Full Report and Discover More
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion " for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
Breast Cancer Therapeutics Market: Analysis North America,Europe,Asia,Rest of World (ROW) - US,Canada,Germany,UK,China - Size and Forecast
Cancer Biologics Market: Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, China - Size and Forecast
Bispecific Antibodies for Cancer Market: Analysis North America, Europe, Asia, Rest of World (ROW) - US, Ireland, China, Hungary, India - Size and Forecast
The field of oncology, particularly in breast cancer treatment, is advancing with precision medicine approaches utilizing systemic therapies such as trispecific monoclonal antibodies. These therapies target specific markers like hormonal receptors and BRCA gene mutations, aiding in neoadjuvant therapy to shrink tumors before surgery. However, side effects including fatigue, headache, and muscle pain, along with potential allergic reactions like rashes and hives, are managed with molecular IgG and laboratory-produced molecules. Precision in therapy is ensured with Fabs and Fc regions of antibodies, which exhibit stereo-specificity in binding to cancerous cells while sparing healthy ones. Combining treatments such as radiation and chemotherapy drugs also inhibits cancer growth and blood vessel formation, offering comprehensive care for patients undergoing breast cancer treatment. Systemic therapy, tailored to hormonal receptor status, addresses symptoms like nausea/vomiting, difficulty in breathing, and bleeding, supporting comprehensive treatment for cancer patients.
Market Scope |
|
Report Coverage |
Details |
Page number |
182 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 13.97% |
Market growth 2024-2028 |
USD 19.2 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
12.02 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 41% |
Key countries |
US, France, China, The Netherlands, and Canada |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celldex Therapeutics Inc, Celltrion Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Johnson and Johnson Services Inc., MacroGenics Inc., Merck KGaA, Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Sanofi SA, Seagen Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, Market growth and Forecasting, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for market forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.